Pfizer will continue providing full funding for the costs of research to discover and develop novel small molecule RORgamma modulators.
Target for the treatment of autoimmune diseases, RORgamma directly controls the production and secretion of a major contributor to inflammation, the cytokine IL-17.
Karo Bio CEO Per Bengtsson said, "The decision illustrates the potential of the science behind RORgamma and its application to the treatment of autoimmune diseases."
According to the collaboration that began in December 2011, Pfizer is responsible for all research costs associated with the project and Karo is eligible for more than $200m in milestone payments besides any royalty fees.